Workflow
icon
Search documents
MongoDB: Growth Surprise Is Coming (NASDAQ:MDB)
Seeking Alpha· 2026-03-31 17:10
I recently joined The REIT Forum and if you are looking for more investment ideas like this one, get them exclusively at The REIT Forum with access to our subscriber-only portfolios.When I last wrote about MongoDB ( MDB ), I compared its positioning and operational rigor it demonstrated over the prior two quarters, similar to that of Palantir ( PLTR ), that allowed the company toAmrita runs a boutique family office fund in beautiful Vancouver, where she leads the investment strategy for the family fund. The ...
BitGo Adds Trading and Settlement for Canton Coin
FinanceFeeds· 2026-03-31 17:09
BitGo Adds Trading and Settlement for Canton Coin BitGo has announced expanded support for Canton Coin, adding electronic trading and settlement capabilities through Go Network. The update builds on the company’s existing over-the-counter trading offering and positions the platform as a single access point for custody, execution, and settlement of the asset.The development comes as infrastructure providers compete to offer integrated services for institutional digital asset activity. Rather than relying on ...
Snap climbs 13% as activist Irenic suggests changes to boost stock's value 7x
CNBC· 2026-03-31 17:09
Evan Spiegel, CEO of Snap Inc., speaks onstage during the Snap Partner Summit 2023 at Barker Hangar on April 19, 2023 in Santa Monica, California.Shares of Snap climbed 13% Tuesday after shareholder Irenic Capital Management sent a letter to CEO Evan Spiegel outlining changes that could increase the stock's value by almost 600%."Snap should not continue doing what it has been doing. It's not working," Irenic wrote in its letter, published on savesnapnow.com alongside a presentation of recommendations.Accord ...
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
Globenewswire· 2026-03-31 17:09
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aldeyra Therapeutics, Inc., (“Aldeyra” or the "Company") (NASDAQ: ALDX) investors of a class action on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”). Aldeyra investors have until May 29, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their l ...
3 Reasons to Buy NewLake Capital Partners Stock and 1 Reason Not To
Yahoo Finance· 2026-03-31 17:08
NewLake Capital Partners (OTC: NLCP) is one of the few real estate investment trusts (REITs) that serve the cannabis industry. While pot stocks have seen a lot of ups and downs over the past few years, NewLake has charted a steadier course, though it is down more than 6% so far this year. That recent dip may actually represent a disconnect between market sentiment and operational reality. While the broader cannabis industry remains volatile due to price compression and the slow pace of change on the federa ...
Could Uncertainty in the Middle East Drive These Four Renewable Energy Stocks to New Highs?
FX Empire· 2026-03-31 17:07
Brookfield Renewable generated $1.3 billion in funds from operations (FFO) in 2025, or $2.01 per share, representing 10% growth from the year prior. These figures are expected to grow comfortably over the months ahead as a renewed emphasis on clean energy drives more client activity.Prior to the conflict in the Middle East, the company forecasted that rising demand for renewables could help to power more than 10% annual FFO per share growth through at least 2030, supporting dividend growth of 5% to 9% in th ...
Wall Street resets Amazon stock price targets on AWS AI trends
Yahoo Finance· 2026-03-31 17:07
Amazon stock is down about 11% year-to-date, but Wall Street is starting to lean more bullish again. The shift comes as AWS growth reaccelerates, driven by strong demand for AI workloads. At the same time, Amazon’s advertising business continues to scale into a larger profit driver, giving the company a stronger long-term earnings base. That’s what makes the stock interesting right now. Amazon is pulling its business in two directions at once. Demand across cloud and AI is clearly strengthening, but t ...
Tilray Brands' Q3 Earnings on the Horizon: What's in The Offing?
ZACKS· 2026-03-31 17:06
Key Takeaways TLRY is likely to report revenues of $205.9M, up 10.9%, with loss narrowing to 14 cents per share.Tilray Brands is expanding cannabis, beverages and wellness, with a focus on higher-margin Europe markets.TLRY faces margin pressure from cannabis mix and weak beverage segment despite turnaround efforts.Tilray Brands, Inc. (TLRY) is expected to report third-quarter fiscal 2026 results on April 1, 2026, before the opening bell.The Zacks Consensus Estimate for revenues is pegged at $205.9 million, ...
Can NFLX's Content Strength Sustain User Engagement & Revenue Growth?
ZACKS· 2026-03-31 17:06
Key Takeaways Netflix saw 9% branded viewing growth and over 96B hours watched, lifting engagement levels.NFLX ties high-impact content to better retention, lower churn and stronger pricing power.Netflix guides 2026 revenues to $50.7-$51.7B, backed by a strong global content pipeline.Netflix’s (NFLX) content strength remains the primary engine driving user engagement and revenue growth. The company is seeing strong traction from originals, with branded content viewing rising 9% year over year in the second ...
UTHR Stock Rises 12.5% on Promising Data From TETON-1 Tyvaso Study
ZACKS· 2026-03-31 17:06
Key Takeaways UTHR shares rose 12.5% after TETON-1 showed significant lung function improvement in IPF patients.The study met its primary endpoint with 130.1 mL FVC gain and reduced risk of clinical worsening.United Therapeutics plans an FDA filing by summer, backed by strong TETON-1 and TETON-2 results.Shares of United Therapeutics (UTHR) rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 study evaluating nebulized Tyvaso for the treatment of patients with idiopathic ...